Abstract #2508

Investigating Prostate Cancer Aggressiveness with Hyperpolarized 13C-Urea + 13C-Pyruvate Perfusion & Metabolic Imaging of Transgenic Primary and Metastatic Tumors

Hsin-Yu Chen¹, Peder E.Z. Larson^1,2, Robert A. Bok², Cornelius von Morze², Renuka Sriram², Romelyn Delos Santos², Justin Delos Santos², Jeremy W. Gordon², John Kurhanewicz^1,2, and Daniel B. Vigneron^1,2

¹Graduate Program in Bioengineering, UCSF and UC Berkeley, University of California, San Francisco, San Francisco, CA, United States, ²Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States

An unmet clinical need facing the management of prostate cancer is an accurate method for distinguishing aggressive prostate cancer from indolent disease. The project investigated the use of hyperpolarized (HP) ¹³C 3D CS-EPSI imaging of co-polarized ¹³C-urea + ¹³C-pyruvate to provide this distinction by simultaneously measuring metabolism and perfusion. Significantly higher pyruvate-to-lactate conversion rates, k_PL, (P<0.00001) and significantly (P<0.004) lower urea perfusion were detected in high-grade tumors compared to low-grade tumor. Lymph-node metastases demonstrated high metabolic conversion (P>0.8) and urea perfusion not significantly (P>0.4) different than high-grade primary tumor.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.